AMRX
Amneal Pharmaceuticals, Inc. Class A Common Stock
PHARMACEUTICAL PREPARATIONS
Best Pharmaceutical Stocks 2026 →
Amneal Pharmaceuticals (AMRX) Stock: Buy, Sell, or Hold?
$21.71
+0.33 (+1.54%)
▲
5d:
+8.82%
30d:
+10.94%
90d:
+25.71%
Open in Live Scanner
70/30 Portfolio Builder
Earnings: Nov 03, 2026
0d
Protect AMRX Gains
Updated Nov 11, 12:00 AM ET
QUANTITATIVE VERDICT
WAIT
LOW Confidence (49%)
Quality Score
50/100
Position
EXTENDED
30-Day Fair Range
$19.51 – $21.07
Position: EXTENDED
Forward P/E & Valuation
17.6x
STRETCHED
vs 14.0x historical avg
Wall Street Target
$24.29
+11.9% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$19.02 / $22.01
Trend: Strong Uptrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
📊 MIXED SIGNALS: AMRX shows conflicting indicators. Wait for confirmation before entering.
Get Alerted When AMRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$26.96
Based on 9.4% avg growth
INTRINSIC VALUE TODAY
$16.74
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 14.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: AMRX is currently trading at $21.71, which is considered extended relative to its 30-day fair value range of $19.51 to $21.07. From a valuation perspective, the stock is trading at a premium (Forward PE: 17.6) compared to its historical average (14.0). At these levels, the market is pricing in 8.1% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, AMRX is in a strong uptrend. The price is approaching resistance at $22.00. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock scores a mixed 44/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $24.29 (+11.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, AMRX is in a strong uptrend. The price is approaching resistance at $22.00. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock scores a mixed 44/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $24.29 (+11.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$19.51 -
$21.07
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
48.6%
Trading Range & Key Levels
30-Day Trading Range
$19.51 -
$21.07
Current vs Trading Range
EXTENDED
Support Level
$19.02
Resistance Level
$22.01
Current Trend
Strong Uptrend
Technical data as of
Nov 11, 2026
Protect Your Profits
Holding AMRX? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanQuantitative Signal Breakdown
- BEARISH: Price extended above range
- NEUTRAL: Mixed technical signals (44/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($24.29)
- NEUTRAL: PE elevated vs history but 8.1% growth expectation is conservative given 157% recent growth
- WARNING: Composite score 50/100 in the bottom quintile — this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
17.61
Wall Street Target
$24.29
(+11.9%)
Revenue Growth (YoY)
10.0%
Earnings Growth (YoY)
157.1%
Profit Margin
4.2%
Valuation Premium vs History
+8.1% premium
PE vs Historical
17.6 vs 14.0
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+8.1%
(market-implied from PE analysis)
1-Year Target
$23.47
(+8%)
2-Year Target
$25.37
(+17%)
3-Year Target
$27.42
(+26%)
3-Yr Target (if PE normalizes)
(PE: 18→14)
PE COMPRESSION
$21.80
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 14.8%)
$37.06
(+71%)
Base:
(SPY PE: 17.6, Growth: 14.8%)
$32.86
(+51%)
Bear:
(PE: 14.0, Growth: 14.8%)
$26.12
(+20%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (18x PE), but valuation improves significantly next year (18x PE) as earnings recover.
Forward PE: 18.18 | Forward EPS (Implied): $1.19
Bull Case
$26.21
(+21%)
Analyst growth 15.0%, PE expands to 19.1
Base Case
$21.71
(0%)
Market implied 0.0%, PE stable at 18.2
Bear Case
$16.61
(-24%)
Severe decline -15.0%, PE contracts to 16.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share AMRX Analysis
Share this live AMRX analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (AMRX)
Bullish
3 Retail Mentions
Reddit / WSB Comments
1
Bullish
StockTwits Volume
2 msgs
24h retail stream
Last Tracked
Oct 31, 2026
Daily AI digest
AI Retail Discussion Summary:
Strong third-quarter earnings for $AMRX, driven by blockbuster sales of GLP-1 medications, surpassing expectations and leading to growth in HIV product sales.
Key Retail Themes:
Earnings Report
GLP-1 Medications
HIV Product Sales
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 11, 2026 7:30 PM ET
Data refreshes hourly during market hours. Next update: 8:30 PM
Data refreshes hourly during market hours. Next update: 8:30 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AMRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
29 analysts |
$208 | 23 SELL |
|
ALKS
Alkermes Plc |
STRONG BUY
20 analysts |
$58 | 33 SELL |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 62 BUY |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$687 | 52 HOLD |
|
HROW
Harrow Health Inc |
STRONG BUY
9 analysts |
$63 | 53 HOLD |
Advanced AMRX Option Strategies
Professional options setups generated by AI based on today's AMRX price and gamma walls.
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive AMRX Research Pages
